Analyst RecommendationThe analyst's recommendation for Alpha Tau Medical Ltd is Buy / High Risk with a significant expected share price return.
Clinical TrialsAlpha Tau Medical announced that the first patient has been treated in the U.S. pilot study of Alpha DaRT in patients with pancreatic cancer.
Regulatory ApprovalAlpha Tau Medical announced that it has secured a radioactive material license from the New Hampshire Bureau of Public Health Protection, Radiological Health Section, following completion of the first phase of construction of its commercial scale manufacturing facility in Hudson, NH.